Literature DB >> 24512642

Leishmania mexicana lipophosphoglycan activates ERK and p38 MAP kinase and induces production of proinflammatory cytokines in human macrophages through TLR2 and TLR4.

A Rojas-Bernabé1, O Garcia-Hernández1, C Maldonado-Bernal2, J Delegado-Dominguez1, E Ortega3, L Gutiérrez-Kobeh1, I Becker1, M Aguirre-Garcia1.   

Abstract

Protozoan parasites of genus Leishmania are the causative agents of leishmaniasis. Leishmania promastigotes primarily infect macrophages in the host, where they transform into amastigotes and multiply. Lipophosphoglycan (LPG), the most abundant surface molecule of the parasite, is a virulence determinant that regulates the host immune response. Promastigotes are able to modulate this effect through LPG, creating a favourable environment for parasite survival, although the mechanisms underlying this modulation remain unknown. We analysed the participation of TLR2 and TLR4 in the production of cytokines and explored the possible phosphorylation of ERK and/or p38 MAP kinase signalling cascades in human macrophages stimulated with Leishmania mexicana LPG. The results show that LPG induced the production of TNF-α, IL-1β, IL-12p40, IL-12p70 and IL-10 and led to phosphorylation of ERK and p38 MAP kinase. Specific inhibitors of ERK or p38 MAP kinases and mAbs against TLR2 and TLR4 reduced cytokine production and phosphorylation of both kinases. Our results suggest that L. mexicana LPG binds TLR2 and TLR4 receptors in human macrophages, leading to ERK and MAP kinase phosphorylation and production of pro-inflammatory cytokines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24512642     DOI: 10.1017/S0031182013002187

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  13 in total

1.  Leishmania donovani Lipophosphoglycan Increases Macrophage-Dependent Chemotaxis of CXCR6-Expressing Cells via CXCL16 Induction.

Authors:  Visnu Chaparro; Louis-Philippe Leroux; Aude Zimmermann; Armando Jardim; Brent Johnston; Albert Descoteaux; Maritza Jaramillo
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

2.  Leishmania enriettii: biochemical characterisation of lipophosphoglycans (LPGs) and glycoinositolphospholipids (GIPLs) and infectivity to Cavia porcellus.

Authors:  Larissa Ferreira Paranaíba; Rafael Ramiro de Assis; Paula Monalisa Nogueira; Ana Claúdia Torrecilhas; João Henrique Campos; Amanda Cardoso de Oliveira Silveira; Olindo Assis Martins-Filho; Natalia Lima Pessoa; Marco Antônio Campos; Patrícia Martins Parreiras; Maria Norma Melo; Nelder de Figueiredo Gontijo; Rodrigo Pedro Pinto Soares
Journal:  Parasit Vectors       Date:  2015-01-17       Impact factor: 3.876

Review 3.  Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate?

Authors:  Claire-Lise Forestier; Qi Gao; Geert-Jan Boons
Journal:  Front Cell Infect Microbiol       Date:  2015-01-21       Impact factor: 5.293

4.  Leishmania infantum Lipophosphoglycan-Deficient Mutants: A Tool to Study Host Cell-Parasite Interplay.

Authors:  Milena Lázaro-Souza; Christine Matte; Jonilson B Lima; Guillermo Arango Duque; Graziele Quintela-Carvalho; Áislan de Carvalho Vivarini; Sara Moura-Pontes; Cláudio P Figueira; Flávio H Jesus-Santos; Ulisses Gazos Lopes; Leonardo P Farias; Théo Araújo-Santos; Albert Descoteaux; Valéria M Borges
Journal:  Front Microbiol       Date:  2018-04-05       Impact factor: 5.640

5.  Leishmania infantum lipophosphoglycan induced-Prostaglandin E2 production in association with PPAR-γ expression via activation of Toll like receptors-1 and 2.

Authors:  Jonilson Berlink Lima; Théo Araújo-Santos; Milena Lázaro-Souza; Alan Brito Carneiro; Izabela Coimbra Ibraim; Flávio Henrique Jesus-Santos; Nívea Farias Luz; Sara de Moura Pontes; Petter Franco Entringer; Albert Descoteaux; Patrícia Torres Bozza; Rodrigo Pedro Soares; Valéria Matos Borges
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

6.  Genetic variation in Interleukin-32 influence the immune response against New World Leishmania species and susceptibility to American Tegumentary Leishmaniasis.

Authors:  Jéssica Cristina Dos Santos; Valéria Bernadete Leite Quixabeira; Muriel Vilela Teodoro Silva; Michelle S M A Damen; Kiki Schraa; Martin Jaeger; Marije Oosting; Samuel T Keating; Miriam Leandro Dorta; Sebastião Alves Pinto; Fernanda Bugalho Duarte; Ledice Inácia de Araújo Pereira; Mihai G Netea; Fátima Ribeiro-Dias; Leo A B Joosten
Journal:  PLoS Negl Trop Dis       Date:  2020-02-05

Review 7.  Glycoconjugates of Gram-negative bacteria and parasitic protozoa - are they similar in orchestrating the innate immune response?

Authors:  Magdalena A Karaś; Anna Turska-Szewczuk; Monika Janczarek; Agnieszka Szuster-Ciesielska
Journal:  Innate Immun       Date:  2019-01       Impact factor: 2.680

8.  MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages.

Authors:  Avijit Goswami; Kamalika Mukherjee; Anup Mazumder; Satarupa Ganguly; Ishita Mukherjee; Saikat Chakrabarti; Syamal Roy; Shyam Sundar; Krishnananda Chattopadhyay; Suvendra N Bhattacharyya
Journal:  EMBO Mol Med       Date:  2020-02-07       Impact factor: 12.137

9.  Metabolomic Analyses of Leishmania Reveal Multiple Species Differences and Large Differences in Amino Acid Metabolism.

Authors:  Gareth D Westrop; Roderick A M Williams; Lijie Wang; Tong Zhang; David G Watson; Ana Marta Silva; Graham H Coombs
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  Lipophosphoglycans from Leishmania amazonensis Strains Display Immunomodulatory Properties via TLR4 and Do Not Affect Sand Fly Infection.

Authors:  Paula M Nogueira; Rafael R Assis; Ana C Torrecilhas; Elvira M Saraiva; Natália L Pessoa; Marco A Campos; Eric F Marialva; Cláudia M Ríos-Velasquez; Felipe A Pessoa; Nágila F Secundino; Jerônimo N Rugani; Elsa Nieves; Salvatore J Turco; Maria N Melo; Rodrigo P Soares
Journal:  PLoS Negl Trop Dis       Date:  2016-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.